Cited by 421Erythropoietin and Anemia TreatmentBiosimilars and Bioanalytical MethodsHemoglobin structure and function

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.

Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin

Open access

Egrie, Joan C, Dwyer, Erik, Browne, Jeffrey K, Hitz, Anna, Lykos, Michele A·2003·Experimental Hematology

Open this paper in CoChat — free account Open PDF

Abstract

Objective Experiments on human erythropoietin (EPO) demonstrated that there is a direct relationship between the sialic acid-containing carbohydrate content of EPO, its circulating half-life, and in vivo bioactivity. This led to the hypothesis that an EPO analogue engineered to contain additional oligosaccharide chains would have enhanced biological activity. Darbepoetin alfa, a hyperglycosylated recombinant human EPO (rHuEPO) analogue with two extra carbohydrate chains, was designed and developed to test this hypothesis. Materials and methods Comparative pharmacokinetic and pharmacodynamic studies and biochemical analyses of darbepoetin alfa and rHuEPO were performed to define the consequences of the increased carbohydrate content. Results Due to its increased sialic acid-containing carbohydrate content, darbepoetin alfa has a higher molecular weight, a greater negative charge, and a approximately fourfold lower EPO receptor binding activity than rHuEPO. It also has a threefold longer circulating half-life than rHuEPO in rats and dogs. In spite of its lower receptor binding, and perhaps counterintuitively, darbepoetin alfa is significantly more potent in vivo than rHuEPO. Due to the pharmacokinetic differences, the relative potency of the two molecules varies as a function of the dosing frequency. Darbepoetin alfa is 3.6-fold more potent than rHuEPO in increasing the hematocrit of normal mice when each is administered thrice weekly, but when the administration frequency is reduced to once weekly, darbepoetin alfa is approximately 13-fold to 14-fold more potent than rHuEPO. Conclusions Increasing the sialic acid-containing carbohydrate content beyond the maximum found in EPO leads to a molecule with a longer circulating half-life and thereby an increased in vivo potency that can be administered less frequently.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/s0301-472x(03)00006-7

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4
LAEMMLI, U. K. (1970) · Nature · doi:10.1038/227680a0 · Cited by 249,961
THE PREPARATION OF 131I-LABELLED HUMAN GROWTH HORMONE OF HIGH SPECIFIC RADIOACTIVITY
Greenwood, F. C., Hunter, W., & GLOVER, J. S. (1963) · Biochemical Journal · doi:10.1042/bj0890114 · Cited by 10,141
Goodman and Gilman's the Pharmacological Basis of Therapeutics
Stigelman, W. H., & Pharm, D. (1986) · Military Medicine · doi:10.1093/milmed/151.1.386 · Cited by 6,796
Goodman and Gilman's The Pharmacological Basis of Therapeutics
Hastings, R. C. (1996) · JAMA · doi:10.1001/jama.1996.03540120077042 · Cited by 2,375
Correction of the Anemia of End-Stage Renal Disease with Recombinant Human Erythropoietin
Eschbach, J. W., Egrie, J. C., Downing, M. R., Browne, J. K., & Adamson, J. W. (1987) · New England Journal of Medicine · doi:10.1056/nejm198701083160203 · Cited by 1,987
Self-citation
EFFECT OF HUMAN ERYTHROPOIETIN DERIVED FROM RECOMBINANT DNA ON THE ANAEMIA OF PATIENTS MAINTAINED BY CHRONIC HAEMODIALYSIS
Winearls, C., Pippard, M. J., Downing, M. R., Oliver, D., Reid, C. D. L., & Cotes, P. M. (1986) · The Lancet · doi:10.1016/s0140-6736(86)92192-6 · Cited by 1,401
Applied Biopharmaceutics and Pharmacokinetics.
(1981) · Annals of Internal Medicine · doi:10.7326/0003-4819-94-6-826_2 · Cited by 1,209
Erythropoietin
Krantz, S. B. (1991) · Blood · doi:10.1182/blood.v77.3.419.419 · Cited by 881
Recombinant Human Erythropoietin in Anemic Patients with End-Stage Renal Disease: Results of a Phase III Multicenter Clinical Trial
Eschbach, J. W., Abdulhadi, M. H., Browne, J. K., Delano, B. G., Downing, M. R., Egrie, J. C., Evans, R. W., Friedman, E. A., Graber, S. E., Haley, N. R., et al. (1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-111-12-992 · Cited by 795
Self-citation
Expression cloning of the murine erythropoietin receptor
D’Andrea, A. D., Lodish, H. F., & Wong, G. G. (1989) · Cell · doi:10.1016/0092-8674(89)90965-3 · Cited by 737

Show all 47 references

Research works printed but not linked: 1

Sowade, 1998, The safety of treatment with recombinant human erythropoietin in clinical use, Int J Mol Med., 1, 303

Sorted by citations

Items 201–300 of 421

Darbepoetin??Alfa
Siddiqui, M. A. A., & Keating, G. M. (2006) · Drugs · doi:10.2165/00003495-200666070-00018 · Cited by 15
Addition of Darbepoetin Alfa to Dose-Dense Chemotherapy: Results From a Randomized Phase II Trial in Small-Cell Lung Cancer Patients Receiving Carboplatin Plus Etoposide
Nagel, S., Kellner, O., Engel-Riedel, W., Guetz, S., Schumann, C., Gieseler, F., & Schuette, W. (2011) · Clinical Lung Cancer · doi:10.3816/clc.2011.n.009 · Cited by 14
The comparative effects of recombinant human erythropoietin and darbepoetin-alpha on cerebral vasospasm following experimental subarachnoid hemorrhage in the rabbit
Kertmen, H., Gürer, B., Yılmaz, E. R., Arıkök, A. T., Kanat, M. A., Ergüder, B. İ., & Şekerci, Z. (2014) · Acta Neurochirurgica · doi:10.1007/s00701-014-2008-x · Cited by 14
The Effect of Darbepoetin Alfa on Growth, Oxygenation and Radioresponsiveness of a Breast Adenocarcinoma
Kirkpatrick, J. P., Hardee, M. E., Snyder, S. A., Peltz, C. M., Zhao, Y., Brizel, D. M., Dewhirst, M. W., & Blackwell, K. (2006) · Radiation Research · doi:10.1667/rr3499.1 · Cited by 14
The Impact of Sialic Acids on the Pharmacokinetics of a PEGylated Erythropoietin
Liu, L., Li, H., Hamilton, S. R., Gomathinayagam, S., Rayfield, W. J., van Maanen, M., Yin, K., Hong, L., & Prueksaritanont, T. (2012) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23320 · Cited by 14
A comparison of haemoglobin levels and doses in haemodialysis patients treated with subcutaneous or intravenous darbepoetin alfa: a German prospective, randomized, multicentre study
Bömmer, J., Asmus, G., Wenning, M., & Bommer, G. (2008) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfn416 · Cited by 14
New erythropoietic proteins: rationale and clinical data
Österborg, A. (2004) · Seminars in Oncology · doi:10.1053/j.seminoncol.2004.04.005 · Cited by 14
De novo weekly and biweekly darbepoetin alfa dosing in pediatric patients with chronic kidney disease
Warady, B. A., Barcia, J. P., Benador, N. M., Jankauskienė, A., Olson, K. A., Podracká, Ľ., Shavkin, A., Srivaths, P. R., Wong, C. J., & Petersen, J. (2017) · Pediatric Nephrology · doi:10.1007/s00467-017-3758-5 · Cited by 13
An integrated modular framework for modeling the effect of ammonium on the sialylation process of monoclonal antibodies produced by CHO cells
Savizi, I. S. P., Motamedian, E., Lewis, N. E., del Val, I. J., & Shojaosadati, S. A. (2021) · Biotechnology Journal · doi:10.1002/biot.202100019 · Cited by 13
Sensitive determination of rhodamine 110-labeled monosaccharides in glycoprotein by capillary electrophoresis with laser-induced fluorescence detection
Ijiri, S., Todoroki, K., Yoshida, H., Yoshitake, T., Nohta, H., & Yamaguchi, M. (2010) · Journal of Chromatography A · doi:10.1016/j.chroma.2010.02.076 · Cited by 13
Darbepoetin alfa in anemia of myelodysplastic syndromes: present and beyond
Kelaïdi, C., & Fenaux, P. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712591003709713 · Cited by 13
Design, modeling, and expression of erythropoietin cysteine analogs in Pichia pastoris: Improvement of mean residence times and in vivo activities through cysteine-specific PEGylation
Maleki, A., Madadkar‐Sobhani, A., Roohvand, F., Najafabadi, A. R., Shafiee, A., Khanahmad, H., Cohan, R. A., Namvar, N. A., & Tajerzadeh, H. (2011) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2011.10.017 · Cited by 13
Construction and analysis of a novel peptide tag containing an unnatural N-glycosylation site
Kaup, M., Saul, V. V., Lusch, A., Dörsing, J., Blanchard, V., Tauber, R., & Berger, M. (2011) · FEBS Letters · doi:10.1016/j.febslet.2011.06.010 · Cited by 13
A Retrospective Assessment of Pre‐Treatment Variables on the Response to Darbepoetin Alfa After Renal Transplantation
McDevitt, L. M., Smith, L. D., Somerville, T., Corbett, J., & Shihab, F. S. (2005) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2005.00941.x · Cited by 13
Development of Biosimilars—Pharmacokinetic and Pharmacodynamic Considerations
Wang, Y., & Chow, A. T. (2009) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543400903280357 · Cited by 13
Congestive heart failure-related anemia and a role for erythropoietin
Akram, K., & Pearlman, B. L. (2006) · International Journal of Cardiology · doi:10.1016/j.ijcard.2006.05.071 · Cited by 13
Patient and caregiver time burden associated with anaemia treatment in different patient populations
Houts, A. C., Loh, G., Fortner, B. V., & Kallich, J. D. (2006) · Supportive Care in Cancer · doi:10.1007/s00520-006-0075-0 · Cited by 13
The Role of Recombinant Erythropoietin in Childhood Cancer
Shankar, A. (2008) · The Oncologist · doi:10.1634/theoncologist.2007-0126 · Cited by 13
Darbepoetin alfa: a new approach to the treatment of chemotherapy-induced anaemia
Vansteenkiste, J., Rossi, G., & Foote, M. (2003) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.3.3.501 · Cited by 13
Half‐Life Modulating Strategies–An Introduction
Kontermann, R. E. (2012) · Wiley eBooks · doi:10.1002/9783527644827.ch1 · Cited by 15
Effects of CNTO 530, an erythropoietin mimetic‐IgG4 fusion protein, on embryofetal development in rats and rabbits
Martin, P. L., Sachs, C. W., Hoberman, A. M., Jiao, Q., & Bugelski, P. J. (2010) · Birth Defects Research Part B Developmental and Reproductive Toxicology · doi:10.1002/bdrb.20227 · Cited by 12
Preparation of pseudo glycoamino acid and its application to glycopeptide synthesis
Tomabechi, Y., & Inazu, T. (2011) · Tetrahedron Letters · doi:10.1016/j.tetlet.2011.09.121 · Cited by 12
Estimate of maintenance EPO to darbepoetin alfa dose conversion ratio in a hospital-based dialysis patient population
Sharma, A. K., Yee, J., Gandra, S. R., Khan, I., & Petersen, J. (2010) · Current Medical Research and Opinion · doi:10.1185/03007995.2010.526598 · Cited by 12
Post-translational modification of a chimeric EPO-Fc hormone is more important than its molecular size in defining its in vivo hematopoietic activity
Salgado, E. R., Montesino, R., Jiménez, S. P., González, M., Hugues, F., Cabezas, O. I., Pérez, R. M., Saavedra, P., Lamazares, E., Salas-Burgos, A., et al. (2015) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2015.04.012 · Cited by 12
Population pharmacokinetics of darbepoetin alfa in haemodialysis and peritoneal dialysis patients after intravenous administration
Takama, H., Tanaka, H., Nakashima, D., Ogata, H., Uchida, E., Akizawa, T., & Koshikawa, S. (2006) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2006.02756.x · Cited by 12
Risks and Benefits of Erythropoiesis-Stimulating Agents in Cancer Management
Beutel, G., & Ganser, A. (2007) · Seminars in Hematology · doi:10.1053/j.seminhematol.2007.04.004 · Cited by 12
Recent Advances Toward Engineering Glycoproteins Using Modified Yeast Display Platforms
Shenoy, A., & Barb, A. W. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1685-7_9 · Cited by 11
Darbepoetin alfa in the treatment of chemotherapy-induced anaemia
Wauters, I., & Vansteenkiste, J. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712590802652280 · Cited by 11
Novel erythropoietin‐based therapeutic candidates with extra N‐glycan sites that block hematopoiesis but preserve neuroplasticity
Bürgi, M., Aparicio, G. I., Dorella, A., Kratje, R. B., Scorticati, C., & Oggero, M. (2021) · Biotechnology Journal · doi:10.1002/biot.202000455 · Cited by 11
Differential pharmacokinetic analysis ofin vivoerythropoietin receptor interaction with erythropoietin and continuous erythropoietin receptor activator in sheep
Elkomy, M. H., Schmidt, R. L., Widness, J. A., & Veng‐Pedersen, P. (2011) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.757 · Cited by 11
Incorporating novel agents in the treatment of myelodysplastic syndromes
Anargyrou, K., Vassilakopoulos, T. P., Angelopoulou, M. K., & Terpos, E. (2009) · Leukemia Research · doi:10.1016/j.leukres.2009.07.021 · Cited by 11
Effect of darbepoetin alfa administered once monthly on maintaining hemoglobin levels in older patients with chronic kidney disease
Silver, M. R., Agarwal, A. K., Krause, M. W., Lei, L., & Stehman‐Breen, C. O. (2008) · The American Journal of Geriatric Pharmacotherapy · doi:10.1016/j.amjopharm.2008.05.002 · Cited by 11
Effects of long-acting erythropoietin analog darbepoetin-α on adriamycin-induced chronic nephropathy
Hussein, A. M., Eldosoky, M., Handhle, A., Elserougy, H. G., Sarhan, M., Sobh, M. A. K., Hussiny, M. E., & Nashar, E. M. E. (2015) · International Urology and Nephrology · doi:10.1007/s11255-015-1171-1 · Cited by 10
The use of a recombinant equine chorionic gonadotropin (reCG) in fixed-time AI programs in beef cattle
Cattaneo, L., Prieto, C. C., Ojeda, D., Pereira, A. S. C., Frutos, J., & Bó, G. A. (2024) · Theriogenology · doi:10.1016/j.theriogenology.2024.07.011 · Cited by 10
Development and validation of a method for analyzing the sialylated glycopeptides of recombinant erythropoietin in urine using LC–HRMS
Seo, Y., Park, J., Lee, H.-J., Kim, M., Kang, I., Son, J. J., Oh, M., & Min, H. (2023) · Scientific Reports · doi:10.1038/s41598-023-31030-y · Cited by 10
Development and application of potency assays based on genetically modified cells for biological products
Yu, L., Zhou, Y. F., & Junzhi, W. (2023) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2023.115397 · Cited by 10
Application of Quality by Design Paradigm to the Manufacture of Protein Therapeutics
del Val, I. J., Philip, M., Exley, K., Sou, S. N., Kyriakopoulos, S., Polizzi, K. M., & Kontoravdi, C. (2012) · InTech eBooks · doi:10.5772/50261 · Cited by 12
Characterization of Therapeutic Proteins
Struble, E. B., Kirschbaum, N., Liu, J., Marszal, E., & Shapiro, M. (2016) · Topics in medicinal chemistry · doi:10.1007/7355_2015_5005 · Cited by 9
Evaluation of Bioactivity and Pharmacokinetic Characteristics of PEGylatedP.pastoris-Expressed Erythropoietin
Maleki, A., Najafabadi, A. R., Roohvand, F., Shafiee, A., Khanahmad, H., Homa, F., Hedayati, M. H., & Tajerzadeh, H. (2011) · Drug Delivery · doi:10.3109/10717544.2011.600782 · Cited by 10
A prospective observational study of the effectiveness, safety, and effect on fatigue of darbepoetin alfa for the treatment of chemotherapy-induced anaemia
Mel, J. R., Salar, A., Rodriguez, C. A., Alegre, A. M., González, A., Cassinello, J., Montesinos, J., Gasquet, J. A., Sánchez, J., Saigí, E., et al. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802381323 · Cited by 10
Efficacy of Darbepoetin Alfa in the Treatment of Chemotherapy-Induced Anemia in Non-Hodgkin's Lymphoma
Gregory, S. A. (2006) · Supportive Cancer Therapy · doi:10.3816/sct.2006.n.021 · Cited by 10
Multivalency—a way to enhance binding avidities and bioactivity—preliminary applications to EPO
Vadas, O., & Rose, K. (2007) · Journal of Peptide Science · doi:10.1002/psc.794 · Cited by 10
Evaluation of Epoetin Alpha (rHuEPO) and Darbepoetin Alpha (DARB) on Human Burst-colony Formation (BFU-E) in Culture
Jamal, N., Krzyżański, W., Cheung, W. K., Lau, C., & Messner, H. (2006) · Journal of International Medical Research · doi:10.1177/147323000603400105 · Cited by 10
Posttranslational modifications of heterologous proteins expressed in Nicotiana benthamiana
Göritzer, K., Kallolimath, S., & Strasser, R. (2025) · Plant Biotechnology Journal · doi:10.1111/pbi.70176 · Cited by 9
A randomized, controlled trial comparing darbepoetin alfa correction/maintenance dosing with weekly dosing for treating chemotherapy-induced anemia
Kotasek, D., Canon, J.-L. R., Mateos, M., Hedenus, M., Rossi, G., & Taylor, K. M. (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x188053 · Cited by 9
Health Economic Evaluation of Treating Anemia in Cancer Patients Receiving Chemotherapy: A Study in Belgian Hospitals
Spaepen, E., Demarteau, N., Belle, S. V., & Annemans, L. (2008) · The Oncologist · doi:10.1634/theoncologist.2007-0219 · Cited by 9
Insights into the loss of protein sialylation in an fc-fusion protein-producing CHO cell bioprocess
Chen, X., Liu, X., Xiao, Z., Liu, J., Zhao, L., Tan, W., & Fan, L. (2019) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-019-09850-8 · Cited by 9
A new alternative tool to analyse glycosylation in pharmaceutical proteins based on infrared spectroscopy combined with nonlinear support vector regression
Hamla, S., Sacré, P., Derenne, A., Derfoufi, K.-M., Cowper, B., Butré, C. I., Delobel, A., Goormaghtigh, E., Hubert, P., & Ziémons, E. (2022) · The Analyst · doi:10.1039/d1an00697e · Cited by 9
Epoetin beta for the treatment of chemotherapy-induced anemia: an update
Egan, C. G., Galli, L., & Ricci, C. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s77497 · Cited by 9
Darbepoetin alfa (KRN321) is safe and effective when administered subcutaneously once every 2 or 4 weeks to patients on peritoneal dialysis in Japan
KRN321 SCA10 Study Group, Kubota, M., Hiramatsu, M., Yamakawa, M., Fukuhara, S., Morita, S., Iwasaki, M., & Akizawa, T. (2011) · Clinical and Experimental Nephrology · doi:10.1007/s10157-011-0527-9 · Cited by 9
Evaluating erythropoietic agents for the treatment of anaemia in the oncology setting
Gascón, P. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.04.046 · Cited by 9
Sensitive and Comprehensive Analysis of O -Glycosylation in Biotherapeutics: A Case Study of Novel Erythropoiesis Stimulating Protein
Kim, U., Oh, M. J., Seo, Y., Jeon, Y., Eom, J.-H., & An, H. J. (2017) · Bioanalysis · doi:10.4155/bio-2017-0085 · Cited by 9
Cardiorenal Anemia Syndrome: Do Erythropoietin and Iron Therapy Have a Place in the Treatment of Heart Failure?
Pagourelias, E. D., Koumaras, C., Kakafika, A. I., Τζιόμαλος, Κ., Zorou, P. G., Athyros, V. G., & Karagiannis, A. I. (2008) · Angiology · doi:10.1177/0003319708316169 · Cited by 9
Every 3 weeks dosing with darbepoetin alfa: A new paradigm in anaemia management
Vansteenkiste, J. F. (2006) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2006.04.006 · Cited by 9
Program Overview * Conference Program * Conference Posters * Conference Abstracts
Toledo, K. A. D., Fermino, M. L., del Cistia-Andrade, C., Riul, T. B., Rodrigues, L., Alves, R. R., Menjon Muller, V. D., Russo, R. R., Stowell, S. R., Cummings, R. D., et al. (2014) · Glycobiology · doi:10.1093/glycob/cwu087 · Cited by 9
Therapeutic potential of adenovirus-mediated TFF2-CTP-Flag peptide for treatment of colorectal cancer
Dubeykovskaya, Z. A., Duddempudi, P. K., Deng, H., Valenti, G., Cuti, K., Nagar, K. K., Tailor, Y. H., Guha, C., Kitajewski, J., & Wang, T. C. (2018) · Cancer Gene Therapy · doi:10.1038/s41417-018-0036-z · Cited by 8
Emerging Approaches for Enabling RNAi Therapeutics
Mallick, A. M., Tripathi, A., Mishra, S., Mukherjee, A., Dutta, C., Chatterjee, A., & Roy, R. S. (2022) · Chemistry - An Asian Journal · doi:10.1002/asia.202200451 · Cited by 8
Darbepoetin Alpha Reduces Oxidative Stress and Chronic Inflammation in Atherosclerotic Lesions of Apo E Deficient Mice in Experimental Renal Failure
Arend, N., Hilgers, K. F., Câmpean, V., Karpe, B., Cordasic, N., Klanke, B., & Amann, K. (2014) · PLoS ONE · doi:10.1371/journal.pone.0088601 · Cited by 8
Allometry of Factor VIII and Informed Scaling of Next-Generation Therapeutic Proteins
Kosloski, M. P., Pisal, D. S., Mager, D. E., & Balu‐Iyer, S. V. (2013) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23566 · Cited by 8
Chemotherapy-induced anemia: the story of darbepoetin alfa
Vansteenkiste, J., Wauters, I., Elliott, S. G., Glaspy, J. A., & Hedenus, M. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.766593 · Cited by 8
Darbepoietin-alfa has comparable erythropoietic stimulatory effects to recombinant erythropoietin whilst preserving the bone marrow microenvironment
Dewamitta, S. R., Russell, M. R., Nandurkar, H. H., & Walkley, C. R. (2012) · Haematologica · doi:10.3324/haematol.2012.078709 · Cited by 8
Mass spectrometric characterisation of darbepoetin alfa biosimilars with C‐terminal arginine residues
Okano, M., Sato, M. P., & Kageyama, S. (2016) · Drug Testing and Analysis · doi:10.1002/dta.2102 · Cited by 8
Pharmacokinetic study of darbepoetin alfa: Absorption, distribution, and excretion after a single intravenous and subcutaneous administration to rats
Yoshioka, E., Kato, K., Shindo, H., Mitsuoka, C., Kitajima, S., Ogata, H., & MISAIZU, T. (2006) · Xenobiotica · doi:10.1080/00498250600987929 · Cited by 8
The use of darbepoetin alfa for the treatment of chemotherapy-induced anaemia
Vansteenkiste, J., & Wauters, I. (2005) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.6.3.429 · Cited by 8
Anti-EPO and anti-NESP antibodies raised against synthetic peptides that reproduce the minimal amino acid sequence differences between EPO and NESP
Giménez, E., de Bolós, C., Belalcázar, V., Andreu, D., Borràs, E., de la Torre, B. G., Barbosa, J., Segura, J., & Pascual, J. A. (2007) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-007-1334-8 · Cited by 8
Innovative Metrics for Reporting and Comparing the Glycan Structural Profile in Biotherapeutics
Mastrangeli, R., Satwekar, A., & Bierau, H. (2023) · Molecules · doi:10.3390/molecules28083304 · Cited by 7
RETRA: evaluating the transfusion rate with darbepoetin alfa 500 µg every 3 weeks in anaemic cancer patients receiving chemotherapy
Eisterer, W., Hussl, C., Erb, H., Haslbauer, F., Sormann, S., Braun, S., & Jaeger, C. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2010.542134 · Cited by 7
Randomized Equivalence Study Evaluating the Possibility of Switching Hemodialysis Patients Receiving Subcutaneous Human Erythropoietin Directly to Intravenous Darbepoetin Alfa
Chazot, C., Terrat, J. C., Dumoulin, A., Ang, K. S., Gassia, J.-P., Chedid, K., Maurice, F., & Canaud, B. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1k664 · Cited by 7
The impact of sialylation linkage‐type on the pharmacokinetics of recombinant butyrylcholinesterases
Chung, C., Wang, Q., Yang, S., Chough, S., Seo, Y., Cipollo, J. F., Balthasar, J. P., & Betenbaugh, M. J. (2019) · Biotechnology and Bioengineering · doi:10.1002/bit.27174 · Cited by 7
Glycosylation in Cell Culture
Spearman, M. A., & Butler, M. (2014) · Cell engineering · doi:10.1007/978-3-319-10320-4_9 · Cited by 8
Cloning and expression of codon-optimized recombinant darbepoetin alfa in Leishmania tarentolae T7-TR
Kianmehr, A., Golavar, R., Rouintan, M., Mahrooz, A., Fard‐Esfahani, P., Oladnabi, M., Khajeniazi, S., Mostafavi, S. S., & Omidinia, E. (2015) · Protein Expression and Purification · doi:10.1016/j.pep.2015.10.013 · Cited by 7
Intravenously administered darbepoetin alfa once a week could maintain hemoglobin level more efficiently than once every 2 weeks in patients on hemodialysis
Nagaya, H., Inaguma, D., Kitagawa, A., Murata, M., Kamimura, Y., Hamaguchi, K., Tatematsu, M., Suzuki, S., Kurata, K., Yuzawa, Y., et al. (2009) · Clinical and Experimental Nephrology · doi:10.1007/s10157-009-0251-x · Cited by 7
Comparative Assessment of the Effect of Hyper-glycosylation on the Pattern and Kinetics of Degradation of Darbepoetin Alfa using a Stability-Indicating Orthogonal Testing Protocol
Moenes, E. M., Al‐Ghobashy, M. A., Mohamed, A. A., & Salem, M. Y. (2017) · Journal of Chromatography B · doi:10.1016/j.jchromb.2017.10.057 · Cited by 7
OUP accepted manuscript
Samoudi, M., Minuchehr, Z., Harcum, S. W., Tabandeh, F., Yeganeh, N. O., & Khodabandeh, M. (2016) · Protein Engineering Design and Selection · doi:10.1093/protein/gzw058 · Cited by 7
Erythropoietic Factors
Elliott, S. G., Heatherington, A. C., & Foote, M. (2004) · Humana Press eBooks · doi:10.1007/978-1-59259-747-5_6 · Cited by 7
Challenges in Delivery of Biopharmaceuticals; the Need for Advanced Delivery Systems
Nielsen, H. M., & Jørgensen, L. (2009) · doi:10.1002/9780470688397.ch1 · Cited by 7
Darbepoetin alfa in the treatment of anemia in cancer patients undergoing chemotherapy
Wauters, I., & Vansteenkiste, J. (2012) · Expert Review of Anticancer Therapy · doi:10.1586/era.12.117 · Cited by 6
Rational engineering of an erythropoietin fusion protein to treat hypoxia
Lee, J., Vernet, A., Gruber, N. G., Kready, K. M., Burrill, D. R., Way, J. C., & Silver, P. A. (2021) · Protein Engineering Design and Selection · doi:10.1093/protein/gzab025 · Cited by 6
Impact on Health-Related Quality of Life in Kidney Transplant Recipients with Late Posttransplant Anemia Administered Darbepoetin Alfa: Results from the STRATA Study
Bloom, R. D., Bolin, P., Gandra, S. R., Scarlata, D., & Petersen, J. (2011) · Transplantation Proceedings · doi:10.1016/j.transproceed.2011.02.009 · Cited by 6
Darbepoetin alfa once monthly corrects anaemia in patients with chronic kidney disease not on dialysis
Roger, S. D., Колмакова, Е. В., Fung, M. M., Małecki, R., Vinhas, J., Dellanna, F., Thomas, M., Manamley, N., & Ferenczi, S. (2014) · Nephrology · doi:10.1111/nep.12214 · Cited by 6
Structure-Function Relationships for Recombinant Erythropoietins: A Case Study From a Proposed Manufacturing Change With Implications for Erythropoietin Biosimilar Study Designs
Grampp, G. E., McElroy, P. L., Camblin, G., & Pollock, A. S. (2018) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2018.01.018 · Cited by 6
Characterization and minimization of sialic acid degradation in an Fc-fusion protein-producing CHO cell bioprocess
Chen, X., Liu, J., Liu, X., Li, F., Zhao, L., & Tan, W. (2018) · Process Biochemistry · doi:10.1016/j.procbio.2018.08.015 · Cited by 6
Strategies for Modulation of Pharmacokinetics of Recombinant Therapeutic Proteins
Zvonova, E. A., Tyurin, A. A., Soloviev, A., & Goldenkova-Pavlova, I. V. (2018) · Biology Bulletin Reviews · doi:10.1134/s2079086418020093 · Cited by 6
Heterogeneity of IgGs: Role of Production, Processing, and Storage on Structure and Function
Barton, C., Spencer, D., Levitskaya, S. V., Feng, J., Harris, R. J., & Schenerman, M. A. (2014) · ACS symposium series · doi:10.1021/bk-2014-1176.ch003 · Cited by 6
Site‐Specific Introduction of Sialic Acid into Insulin
Sato, M., Sadamoto, R., Niikura, K., Monde, K., Kondo, H., & Nishimura, S. (2004) · Angewandte Chemie · doi:10.1002/ange.200353058 · Cited by 6
Novel Formulation Approaches for Peptide and Protein Injectables
Yang, M., & Frøkjær, S. (2009) · Wiley eBooks · doi:10.1002/9780470688397.ch2 · Cited by 6
The Influence of Artificially Introduced N-Glycosylation Sites on the In Vitro Activity of Xenopus laevis Erythropoietin
Nagasawa, K., Meguro, M., Sato, K., Tanizaki, Y., Nogawa-Kosaka, N., & Kato, T. (2015) · PLoS ONE · doi:10.1371/journal.pone.0124676 · Cited by 5
Differential Effects of Long-lived Erythropoietin Receptor Agonists in Rats
Bugelski, P. J., Makropoulos, D., & Doms, T. S. (2011) · Pharmaceutica Analytica Acta · doi:10.4172/2153-2435.1000133 · Cited by 5
Synthesis in Escherichia coli and Characterization of Human Recombinant Erythropoietin with Additional Heparin-Binding Domain
Karyagina, A. S., Grunina, T. M., Poponova, M. S., Orlova, P. A., Манских, В. Н., Демиденко, А. В., Strukova, N. V., Manukhina, M. S., Nikitin, K. E., Lyaschuk, A. M., et al. (2018) · Biochemistry (Moscow) · doi:10.1134/s0006297918100061 · Cited by 5
The site-specific TGase-mediated PEGylation of proteins occurs at flexible sites
Fontana, A., Spolaore, B., Mero, A., & Veronese, F. M. (2009) · Birkhäuser Basel eBooks · doi:10.1007/978-3-7643-8679-5_6 · Cited by 5
Anemia in heart failure: To treat or not to treat?
Mak, G. J., Murphy, N. F., & McDonald, K. (2008) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-008-0038-5 · Cited by 5
Darbepoetin ?? as treatment for anemia in patients receiving chemotherapy: a single-center experience
Bartsch, R., Wenzel, C., Sevelda, U., Hussian, D., Pluschnig, U., Locker, G. J., Mader, R. M., Zielinski, C. C., & Steger, G. G. (2005) · Anti-Cancer Drugs · doi:10.1097/00001813-200507000-00004 · Cited by 5
Population pharmacokinetics of darbepoetin alfa in peritoneal dialysis and non-dialysis patients with chronic kidney disease after single subcutaneous administration
Kawakami, K., Takama, H., Nakashima, D., Tanaka, H., Uchida, E., & Akizawa, T. (2008) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-008-0561-z · Cited by 5
Darbepoetin alfa: An Effective Treatment with Flexible and Simplified Dosing for Anemia in Patients with Cancer
Stevenson, J. G., & Natale, J. J. (2007) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.27.3.434 · Cited by 5
Use and cost of erythropoiesis-stimulating agents in patients with cancer
Daniel, G. W., Hurley, D., Whyte, J. L., Willey, V. J., Wilson, M., & Kallich, J. D. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903001150 · Cited by 5
Pegfilgrastim — designing an improved form of rmetHuG-CSF
Molineux, G. (2009) · Birkhäuser Basel eBooks · doi:10.1007/978-3-7643-8679-5_10 · Cited by 5
Hematopoietic growth factors
Mazza, J. J., Reding, D. J., & Plank, G. S. (1992) · Postgraduate Medicine · doi:10.1080/00325481.1992.11701380 · Cited by 5
Mammalian Cell Lines and Glycosylation: A Case Study
Butler, M. (2009) · Wiley eBooks · doi:10.1002/9783527626601.ch3 · Cited by 5
Half-life extension and immunogenicity in therapeutic proteins: mechanisms, trade-offs, and a decision framework
Chen, Y., Song, Y., Xie, Y., & Pan, J. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.117846 · Cited by 4
A versatile design platform for glycoengineering therapeutic antibodies
Ludwig, S. D., Bernstein, Z. J., Agatemor, C., Dammen‐Brower, K., Ruffolo, J. A., Rosas, J. M., Post, J. D., Cole, R. N., Yarema, K. J., & Spangler, J. B. (2022) · mAbs · doi:10.1080/19420862.2022.2095704 · Cited by 4

Authors: Egrie, J. C., Dwyer, E., Browne, J. K., Hitz, A., & Lykos, M. A.
Affiliations: Amgen (United States) (US)
Corresponding author: Egrie, Joan C
Venue: Experimental Hematology
Publisher: Elsevier BV
Published: 2003-04
Volume: 31
Issue: 4
Pages: 290-299
ISSN: 0301-472X (ISSN-L)
DOI: 10.1016/s0301-472x(03)00006-7
OpenAlex: W2169177790
Cited by: 421
References: 47
Citations by year: 2026: 10 · 2025: 14 · 2024: 6 · 2023: 7 · 2022: 11 · 2021: 12 · 2020: 3 · 2019: 12 · 2018: 14 · 2017: 12 · 2016: 13 · 2015: 19 · 2014: 16 · 2013: 16 · 2012: 19
FWCI: 16.09
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 7008 d)
Locations: Experimental Hematology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Hemoglobin structure and function
Keywords: darbepoetin alfa, recombinant human erythropoietin, erythropoietin analogues, hyperglycosylation, serum half-life, in vivo potency, hematocrit, dosing frequency, pharmacokinetics, pharmacodynamics
MeSH terms: Darbepoetin alfa, Animals, Carbohydrates, Dogs, Dose-Response Relationship, Drug, Electrochemistry, Electrophoresis, Polyacrylamide Gel, Erythropoietin, Half-Life, Hematocrit, Humans, Kinetics, Male, Molecular Weight, Recombinant Proteins, Rats, Sprague-Dawley, Receptors, Erythropoietin, N-Acetylneuraminic Acid, Mice, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks